View in EDS

Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.

Saved in:
Bibliographic Details
Title: Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
Authors: Páez, David1,2 dpaez@santpau.cat, Tobeña, María1, Fernández-Plana, Julen3, Sebio, Ana1, Virgili, Anna C.1,4, Cirera, Lluís3, Barnadas, Agustí1, Riera, Pau5,6, Sullivan, Ivana1, Salazar, Juliana2,5
Source: British Journal of Cancer. Jan2019, Vol. 120 Issue 2, p190-195. 6p. 1 Diagram, 5 Charts.
Database: Academic Search Ultimate
Description
ISSN:00070920
DOI:10.1038/s41416-018-0348-7